Three absurdly cheap dividend stocks that are trading at modest multiples of their expected earnings today are Merck (NYSE: ...

The next referendum on Gilead Sciences’ oft-criticized oncology business is approaching. Circle Nov. 5 on your calendars.

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $87.23, denoting a -1.05% change from the preceding trading day.

The Center, Native Son, and Gilead present Black, Queer, & Here, a 2024 election forum on key issues facing the Black LGBTQ+ ...

Charting, Price Performance, News & Related Contracts.

A 33-year-old man presented to our dermatology clinic with a 1-month history of two painless ulcers on his right arm and ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,150.00.

It has been a decent year for the biotech industry so far, buoyed by new drug approvals and positive regulatory/pipeline updates. The third-quarter earnings season has just kicked off, with most major ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

As of 1530 BST, the Dow Jones Industrial Average was down 0.22% at 42,421.71, while the S&P 500 advanced 0.16% to 5,806.89 ...

Aspen Aerogels (NYSE:ASPN – Get Free Report) had its target price lowered by equities researchers at Piper Sandler from $36.00 to $33.00 in a report released on Tuesday, Benzinga reports. The firm ...